Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1207 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Xeomin (Botulinum neurotoxin type A) for lower limb and/or upper limb spasticity	Botulinum toxin A (Dysport; AbobotulinumtoxinA; Xeomin; Incobotulinumtoxin A; ANT-1207; Botox; OnabotulinumtoxinA; RT002; Daxibotulinumtoxin A; Azzalure; RT-001; NT 201; AGN-151607)	Lower limb spasticity , Upper limb spasticity	Musculoskeletal System	2023	View \| Download
Xeomin for sialorrhea in children and adolescents aged 2 to 17 years	Botulinum toxin A (Dysport; AbobotulinumtoxinA; Xeomin; Incobotulinumtoxin A; ANT-1207; Botox; OnabotulinumtoxinA; RT002; Daxibotulinumtoxin A; Azzalure; RT-001; NT 201; AGN-151607)	Sialorrhea	Dental and Oral Health	2020	View \| Download
Xevinapant with platinum-based chemoradiotherapy for previously untreated locally advanced squamous cell carcinoma of the head and neck	Xevinapant (Debio 1143; AT-406)	Head and neck cancer	Head and Neck Cancer	2022	View \| Download
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies	Zamtocabtagene autoleucel	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma	Zamtocabtagene autoleucel	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanidatamab for treating advanced or metastatic HER2-positive biliary tract cancer in adults	Zanidatamab (ZW-25)	Biliary tract cancer	Gastrointestinal Cancer	2023	View \| Download
Zanubrutinib for previously treated mantle cell lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanubrutinib for treating marginal zone lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Marginal zone lymphoma (MZL)	Haematological Cancer and Lymphomas	2022	View \| Download